Published in Cell on November 24, 2004
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer (2006) 8.83
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
p53 polymorphisms: cancer implications. Nat Rev Cancer (2009) 3.33
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage. Mol Cell (2008) 2.70
Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA (2011) 2.61
A polymorphic p53 response element in KIT ligand influences cancer risk and has undergone natural selection. Cell (2013) 2.60
Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev (2006) 2.35
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A (2008) 2.22
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
The ups and downs of p53: understanding protein dynamics in single cells. Nat Rev Cancer (2009) 2.13
Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res (2008) 2.04
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer (2005) 1.83
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78
Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma (2011) 1.69
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J (2008) 1.65
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol (2007) 1.64
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci U S A (2007) 1.56
Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Med (2006) 1.55
MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene (2011) 1.54
Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Proc Natl Acad Sci U S A (2009) 1.54
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50
Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A (2005) 1.49
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell (2010) 1.49
Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. PLoS One (2015) 1.45
Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev (2005) 1.42
Analytical methods for inferring functional effects of single base pair substitutions in human cancers. Hum Genet (2009) 1.39
Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. Genes Cancer (2010) 1.38
5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint. Cell Rep (2013) 1.37
MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet (2006) 1.35
The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet (2005) 1.34
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res (2012) 1.33
Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol (2010) 1.31
Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol (2009) 1.30
Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet (2009) 1.29
Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A (2007) 1.28
Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol (2008) 1.25
The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol (2010) 1.23
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem (2014) 1.21
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res (2006) 1.19
Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci U S A (2005) 1.18
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res (2010) 1.18
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 1.18
Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One (2013) 1.16
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res (2011) 1.16
A survey of genomic properties for the detection of regulatory polymorphisms. PLoS Comput Biol (2007) 1.14
Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res (2014) 1.14
A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol (2007) 1.13
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget (2011) 1.11
Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 1.10
Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics (2006) 1.10
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis (2004) 1.10
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res (2010) 1.10
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res (2007) 1.08
Regulation of female reproduction by p53 and its family members. FASEB J (2011) 1.08
Life in the fast lane: mammalian disease models in the genomics era. Cell (2012) 1.08
Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog (2011) 1.07
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia (2009) 1.07
Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One (2012) 1.06
LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun (2014) 1.06
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer (2008) 1.06
Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med (2009) 1.06
The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes Cancer (2012) 1.06
Visualization and targeted disruption of protein interactions in living cells. Nat Commun (2013) 1.05
Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk. Am J Pathol (2007) 1.05
Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol (2012) 1.04
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell (2014) 1.04
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis (2009) 1.03
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One (2011) 1.03
The role of p53 gene family in reproduction. Cold Spring Harb Perspect Biol (2009) 1.03
Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer (2008) 1.02
Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res (2009) 1.01
Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol (2008) 1.01
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res (2009) 1.01
Multi-species, multi-transcription factor binding highlights conserved control of tissue-specific biological pathways. Elife (2014) 1.01
A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem (2009) 1.01
Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription (2012) 1.01
HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity. J Biol Chem (2010) 1.00
Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer (2010) 0.99
Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death Differ (2009) 0.99
Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res (2007) 0.99
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn (2006) 0.99
MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 0.98
MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol (2011) 0.98
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer (2006) 0.98
Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development. Breast Cancer Res (2011) 0.98
Stochastic gene expression in a single cell. Science (2002) 34.54
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet (2004) 8.30
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A (2005) 7.38
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol (2009) 5.86
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet (2007) 5.02
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
p53 regulates maternal reproduction through LIF. Nature (2007) 4.12
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet (2011) 3.92
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res (2007) 3.55
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23
The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res (2006) 3.22
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer (2010) 3.11
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol (2010) 3.06
Framingham Heart Study 100K Project: genome-wide associations for blood pressure and arterial stiffness. BMC Med Genet (2007) 3.04
MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets (2005) 3.04
Genetic associations with valvular calcification and aortic stenosis. N Engl J Med (2013) 3.02
Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet (2007) 2.93
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc Natl Acad Sci U S A (2008) 2.90
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet (2010) 2.76
Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair. Proc Natl Acad Sci U S A (2006) 2.74
Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun (2013) 2.72
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem (2002) 2.68
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet (2003) 2.52
Allele-specific p53 mutant reactivation. Cancer Cell (2012) 2.51
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci U S A (2010) 2.47
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol (2010) 2.33
Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. PLoS Pathog (2010) 2.32
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32
Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med (2006) 2.28
High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med (2012) 2.20
Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell (2006) 2.14
Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension (2011) 2.13
Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol (2009) 2.10
Comparison of avian and human influenza A viruses reveals a mutational bias on the viral genomes. J Virol (2006) 2.06
Highly conserved regions of influenza a virus polymerase gene segments are critical for efficient viral RNA packaging. J Virol (2007) 2.05
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell (2012) 2.04
Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study. BMC Med Genet (2007) 2.00
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood (2008) 1.98
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
Patterns of evolution and host gene mimicry in influenza and other RNA viruses. PLoS Pathog (2008) 1.96
Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation (2011) 1.96
Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst (2002) 1.95
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 1.95
The early repolarization pattern in the general population: clinical correlates and heritability. J Am Coll Cardiol (2011) 1.95
A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol (2010) 1.95
Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst (2007) 1.94
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol (2003) 1.93
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
Tissue-specific codon usage and the expression of human genes. Proc Natl Acad Sci U S A (2004) 1.91
Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. PLoS Genet (2010) 1.91